Differential expression of 37 selected genes in hormone-refractory prostate cancer using quantitative taqman real-time RT-PCR

被引:17
作者
Fromont, G
Chene, L
Vidaud, M
Vallancien, G
Mangin, P
Fournier, G
Validire, P
Latil, A
Cussenot, O
机构
[1] Inst Montsouris, Dept Pathol, F-75014 Paris, France
[2] Univ Paris 07, Ctr Etud & Rech Pathol Prostat 3104, Paris, France
[3] Inst Montsouris, Dept Urol, F-75014 Paris, France
[4] Genopole, Urogene, Evry, France
[5] Fac Sci Pharmaceut & Biol Paris, Mol Genet Lab, Equipe Associee 3618, Paris, France
[6] Ctr Hosp Univ Nancy, Dept Urol, Nancy, France
[7] CHU Brest, Dept Urol, F-29285 Brest, France
关键词
prostate cancer; disease progression; quantitative evaluation;
D O I
10.1002/ijc.20704
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Progression of prostate cancer to androgen independence remains the primary obstacle to improved survival. The development of more effective treatments depends on our understanding of the molecular events associated with the hormone-refractory stage. We quantified, among 90 screened genes, the expression of 37 target genes, using real-time quantitative RT-PCR. Gene expression was studied in 13 samples of HPRC compared to 33 clinically localised cancers and normal prostate tissue. We identify 19 genes with significant differential expression in HRPC compared to localised prostate cancer. Genes with decreased expression included receptors for growth factors, MMR genes and the serine protease hepsin. Analysis of increased gene expression confirmed the importance of AR upregulation and highlighted genes not previously linked to HRPC, including enzymes involved in steroid synthesis and the antiapoptotic factor survivin. Progression of prostate cancer to the hormone-refractory state is associated with differential gene expression, which may prove useful for both understanding disease progression and the development of new therapeutic approaches. (C) 2004 Wiley-Liss, Inc.
引用
收藏
页码:174 / 181
页数:8
相关论文
共 51 条
  • [1] Neuroendocrine cells in tumour growth of the prostate
    Abrahamsson, PA
    [J]. ENDOCRINE-RELATED CANCER, 1999, 6 (04) : 503 - 519
  • [2] Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
    Agus, DB
    Akita, RW
    Fox, WD
    Lewis, GD
    Higgins, B
    Pisacane, PI
    Lofgren, JA
    Tindell, C
    Evans, DP
    Maiese, K
    Scher, HI
    Sliwkowski, MX
    [J]. CANCER CELL, 2002, 2 (02) : 127 - 137
  • [3] BASIC LOCAL ALIGNMENT SEARCH TOOL
    ALTSCHUL, SF
    GISH, W
    MILLER, W
    MYERS, EW
    LIPMAN, DJ
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 1990, 215 (03) : 403 - 410
  • [4] Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault
    Arnold, JT
    Isaacs, JT
    [J]. ENDOCRINE-RELATED CANCER, 2002, 9 (01) : 61 - 73
  • [5] Bookstein R, 2001, CONT CANC RES, P61
  • [6] Aberrant expression of gastrin-releasing peptide and its receptor by well-differentiated colon cancers in humans
    Carroll, RE
    Matkowskyj, KA
    Chakrabarti, S
    McDonald, TJ
    Benya, RV
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 1999, 276 (03): : G655 - G665
  • [7] Chang WY, 1999, PROSTATE, V40, P115
  • [8] Chen Y, 2001, CANCER RES, V61, P4112
  • [9] CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
  • [10] Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor
    Chott, A
    Sun, Z
    Morganstern, D
    Pan, J
    Li, T
    Susani, M
    Mosberger, I
    Upton, MP
    Bubley, GJ
    Balk, SP
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 1999, 155 (04) : 1271 - 1279